ALR Technologies SG Ltd. files as a foreign private issuer, and its regulatory documents describe a Singapore-based diabetes management company with ordinary shares traded under ALRTF. The filing record includes Form 6-K current reports, interim consolidated financial statements, management discussion and analysis, controls and procedures, risk factors, legal proceedings, market-risk disclosure, and exhibits tied to company announcements.
Company-specific disclosures cover the GluCurve Pet CGM business, diabetes data-management technology, operating losses and shareholders’ deficit, ordinary-share capital structure, and warrant modifications. The filings also document board and executive-related warrant holdings where those securities are amended or reported in material-event filings.
ALR Technologies SG Ltd. director Ronald Cheng filed an initial statement of ownership showing his current equity position. He directly holds 1,205,800 Ordinary Shares of the company.
He also holds stock options over 5,000,000 Ordinary Shares at an exercise price of $0.01 per share, expiring on June 30, 2028. A prior redomicile merger in November 2022 converted his former ALR Technologies Inc. shares, options, and warrants into equivalent ALR Technologies SG Ltd. securities.
ALR Technologies SG Ltd. files its annual report describing a diabetes data-management business focused on its FDA-cleared Diabetes Solution platform and GluCurve Pet CGM product. The company highlights a manufacturing agreement with CGM Medical Technology Shen Zhen for exclusive global supply of continuous glucose monitors for animal health, subject to performance conditions.
Management states that recurring losses and negative cash flow raise substantial doubt about ALR’s ability to continue as a going concern. The company reported a 2025 net loss of $22,057,792 and an accumulated deficit of $158,043,706 as of December 31, 2025. It had 645,466,844 ordinary shares outstanding and a large overhang of options and warrants. The business depends on securing new capital, reliable CGM supply, distributor performance, regulatory clearances for human-health products, and managing extensive operational, AI, cybersecurity, IP, and regulatory risks.
ALR Technologies SG Ltd. director Stafford Peter H filed an initial ownership report showing his current stake in the company. He holds a stock option over 10,000,000 ordinary shares at an exercise price of $0.01 per share, expiring on June 30, 2028. He also owns 1,375,000 ordinary shares directly and 125,000 ordinary shares indirectly through his spouse. A prior reorganization converted his former ALR Technologies Inc. equity into equivalent ALR Technologies SG Ltd. ordinary shares and options.
ALR Technologies SG Ltd. reported that Corporate Secretary Benjamin Szeto holds a stock option linked to the company’s ordinary shares. The option covers 10,000,000 underlying ordinary shares at an exercise price of $0.01 per share and expires on June 30, 2028.
The filing explains that this option was converted in connection with a prior redomicile merger, where securities of ALR Technologies Inc. were exchanged for equivalent securities of ALR Technologies SG Ltd. There are no new purchases or sales; this Form 3 mainly records Szeto’s existing derivative position.
ALR Technologies SG Ltd. director and officer Kan Yuen Shan has filed an initial Form 3 showing substantial direct and indirect holdings in ordinary shares and warrants. The filing lists direct ownership of 193,653,482 ordinary shares and indirect ownership of 189,845,000 ordinary shares held by the reporting person’s spouse.
The report also details multiple warrant positions over ALR ordinary shares with exercise prices ranging from $0.002 to $0.015 per share, all expiring on December 31, 2026. These warrants cover large underlying share amounts held both directly and through the spouse following a prior redomicile merger.
ALR Technologies SG Ltd. director Kenneth Robulak reports his initial ownership of stock options and ordinary shares. He holds several stock option positions over 1,000,000, 2,350,000, 6,650,000 and 8,000,000 ordinary shares, each with a $0.01 exercise price expiring on June 30, 2028, plus 1,190,000 ordinary shares held directly.
A prior redomicile merger converted his former ALR Technologies Inc. equity into equivalent ALR Technologies SG Ltd. ordinary shares and options at the same exercise price.
ALR Technologies SG Ltd. CEO and director Sidney Chan filed an initial Form 3 showing his and related holdings in the company. He reports direct ownership of 189,845,000 Ordinary Shares and indirect ownership of 193,653,482 Ordinary Shares held by his spouse, Christine Kan. The filing also lists large warrant positions over Ordinary Shares with exercise prices between $0.0100 and $0.0200 per share, expiring on December 31, 2026, including 4,210,001,000 underlying shares held directly and 700,000,500 underlying shares held indirectly through his spouse.
ALR Technologies SG Ltd. reports that on December 31, 2026 it modified certain share purchase warrants held by two senior insiders. The company extended the expiry date of 4,910,001,500 warrants held by CEO and Chairman Sidney Chan and VP and director Christine Kan from December 31, 2025 to December 31, 2026. Each warrant is exercisable into one ordinary share at an exercise price of $0.002 per share. This change keeps a large block of low-priced warrants in place for an additional year, preserving potential equity participation for these executives.
ALR Technologies SG Ltd. reports a deepening loss and severe liquidity strain for the six months ended June 30, 2025. Net loss widened to about $10,770,000 from $6,028,000, mainly because interest expense soared to $9,367,270, including $8,187,123 of non-cash share-based compensation from modifying warrants held by the CEO and VP. Core operating expenses actually fell 46% to roughly $1,139,000 as product development, professional, and administrative costs decreased.
The balance sheet is highly stressed. Current liabilities were $38,368,906 versus total assets of only $31,002, leaving a working capital deficit of about $38,338,000 and shareholders’ deficit of $38,337,904. The company had cash of just $1,738 and relies heavily on related-party funding, including $21,164,886 of lines of credit and a $3,822,081 loan. Management discloses substantial doubt about its ability to continue as a going concern, with $11,222,000 of promissory notes and related interest in default and prior default judgments outstanding.
ALR Technologies SG Ltd. filed a report as a foreign private issuer to share a recent company announcement. The filing states that on December 8, 2025, the company issued a press release, which is attached to the report as Exhibit 99.1.
The press release announced the relaunch of the company’s GluCurve Pet CGM, a continuous glucose monitoring product for pets. This report mainly serves to make that product update publicly available to investors through the SEC’s disclosure system.